All In Biotech

Drug Trial Radar · NCT02035137

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Jun 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Jul 2014

Primary completion

Feb 26, 2021

Study completion Feb 26, 2021

Sponsor

Lead sponsor
New Approaches to Neuroblastoma Therapy ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • 131I-MIBGRadiation

  • VincristineDrug

  • IrinotecanDrug

  • VorinostatDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Tumor Response After One Course of TherapyTime frame: 43-50 days from study day 1

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Childrens Hospital Los Angeles

    Los Angeles, California

  • Lucile Salter Packer Children's Hospital

    Palo Alto, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Children Hospital of Colorado

    Aurora, Colorado

  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus

    Atlanta, Georgia

  • University of Chicago, Comer Children's Hospital

    Chicago, Illinois

  • Children's Hospital Boston

    Boston, Massachusetts

  • C.S Mott Children's Hospital

    Ann Arbor, Michigan

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Cook Children's Healthcare System

    Fort Worth, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Hospital for Sick Children

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.